Compare Adaptive Biotechnologies Corp (ADPT) vs Bank of Montreal (BMO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Bank of Montreal — how do they compare? Adaptive Biotechnologies Corp trades at $20.03 (market cap $3.33B), while Bank of Montreal trades at $174.88 (market cap $124.94B). The key difference: Bank of Montreal is far larger — about 37.5× Adaptive Biotechnologies Corp's market cap, and Bank of Montreal pays a 2.78% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BMO | |
|---|---|---|
Market Cap | $3.33B | $124.94B |
Sector | Health | Financials |
52-Week High | $22.37 | $178.25 |
52-Week Low | $10.24 | $110.44 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BMO trades at $178.25, up 2.37% today, with a bullish technical signal and strong analyst support. Recent earnings show a mixed record with a Q1 2026 miss but beats in prior quarters, while revenue and net income have grown steadily. The company maintains a solid dividend history and was recently recognized as Best Commercial Bank in Canada and the U.S. by World Finance Magazine (June 23, 2026).
The outlook is positive given earnings growth and strategic acquisitions, but risks include valuation above historical averages and sensitivity to interest rates. Analyst consensus is evenly split between Buy and Hold, indicating cautious optimism for continued performance amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →
